Biocon Chief Says No Chance For Indian Firm In M&A
This article was originally published in PharmAsia News
The head of India's Biocon biotechnology company says she does not anticipate ever selling her company. Kiran Mazumdar Shaw, chairman and managing director of the firm, said her emotional attachment to the company is too strong for her to consider selling out to another firm, as Ranbaxy Laboratories is doing. She said her loyalty and desire to expand the company probably result from her being a first-generation entrepreneur. It is often the following generations without an emotional attachment to a start-up that are willing to consider mergers and acquisitions, she said. She acknowledged, however, the state of flux in the biotechnology sector presents its own challenge to companies. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.